FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788889277> ?p ?o ?g. }

• W2788889277 endingPage "446" @default.
• W2788889277 startingPage "442" @default.
• W2788889277 abstract "The incidence of endometrial cancer (EC) in the U.S. has been rising, from an estimated annual incidence of 49,560 in 2013 to 61,380 in 2017. Meanwhile, the SEER-based relative survival of women with EC in the U.S. has remained flat [82.3% from 1987 to 1989, 82.8% from 2007 to 2013] and our recent increased understanding of EC biology and subtypes has not been translated into therapeutic advances. The U.S. National Cancer Institute (NCI) therefore convened a Uterine Clinical Trials Planning Meeting in January 2016 to initiate and accelerate design of molecularly-targeted EC trials. Prior to the meeting a group of experts in this field summarized available data, emphasizing data on human samples, to identify potentially actionable alterations in EC, and the results of their work has been separately published. The Clinical Trials Meeting planners focused on discussion of (1) novel trial designs, including window-of opportunity trials and appropriate control groups for randomized trials, (2) targets specific to serous carcinoma and promises and pitfalls of separate trials for women with tumors of this histology (3) specific recommendations for future randomized trials." @default.
• W2788889277 created "2018-03-06" @default.
• W2788889277 creator A5005621340 @default.
• W2788889277 creator A5006308233 @default.
• W2788889277 creator A5011411233 @default.
• W2788889277 creator A5030167766 @default.
• W2788889277 creator A5045621454 @default.
• W2788889277 creator A5046031005 @default.
• W2788889277 creator A5049940232 @default.
• W2788889277 creator A5054372225 @default.
• W2788889277 creator A5068335479 @default.
• W2788889277 creator A5076087889 @default.
• W2788889277 date "2018-06-01" @default.
• W2788889277 modified "2023-10-03" @default.
• W2788889277 title "Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report" @default.
• W2788889277 cites W1487922930 @default.
• W2788889277 cites W1940241680 @default.
• W2788889277 cites W1958951208 @default.
• W2788889277 cites W1965239527 @default.
• W2788889277 cites W1971924476 @default.
• W2788889277 cites W1975352300 @default.
• W2788889277 cites W1976582060 @default.
• W2788889277 cites W1984069313 @default.
• W2788889277 cites W1985046983 @default.
• W2788889277 cites W1987734307 @default.
• W2788889277 cites W1992523140 @default.
• W2788889277 cites W1997486108 @default.
• W2788889277 cites W2003225436 @default.
• W2788889277 cites W2006452977 @default.
• W2788889277 cites W2009109819 @default.
• W2788889277 cites W2023587700 @default.
• W2788889277 cites W2025372445 @default.
• W2788889277 cites W2029650228 @default.
• W2788889277 cites W2041440766 @default.
• W2788889277 cites W2044869180 @default.
• W2788889277 cites W2047331598 @default.
• W2788889277 cites W2052648972 @default.
• W2788889277 cites W2066032552 @default.
• W2788889277 cites W2068659150 @default.
• W2788889277 cites W2070528300 @default.
• W2788889277 cites W2089876863 @default.
• W2788889277 cites W2105906697 @default.
• W2788889277 cites W2109023930 @default.
• W2788889277 cites W2110691972 @default.
• W2788889277 cites W2111163389 @default.
• W2788889277 cites W2118224996 @default.
• W2788889277 cites W2120965358 @default.
• W2788889277 cites W2148407509 @default.
• W2788889277 cites W2151509048 @default.
• W2788889277 cites W2154455853 @default.
• W2788889277 cites W2154516141 @default.
• W2788889277 cites W2169183724 @default.
• W2788889277 cites W2171608750 @default.
• W2788889277 cites W2198558053 @default.
• W2788889277 cites W2295170877 @default.
• W2788889277 cites W2305933219 @default.
• W2788889277 cites W2306919242 @default.
• W2788889277 cites W2308364408 @default.
• W2788889277 cites W2316557830 @default.
• W2788889277 cites W2554763596 @default.
• W2788889277 cites W2588770396 @default.
• W2788889277 cites W2742714490 @default.
• W2788889277 cites W2756076838 @default.
• W2788889277 cites W3003699744 @default.
• W2788889277 doi "https://doi.org/10.1016/j.ygyno.2018.02.005" @default.
• W2788889277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29477660" @default.
• W2788889277 hasPublicationYear "2018" @default.
• W2788889277 type Work @default.
• W2788889277 sameAs 2788889277 @default.
• W2788889277 citedByCount "13" @default.
• W2788889277 countsByYear W27888892772018 @default.
• W2788889277 countsByYear W27888892772019 @default.
• W2788889277 countsByYear W27888892772020 @default.
• W2788889277 countsByYear W27888892772021 @default.
• W2788889277 countsByYear W27888892772023 @default.
• W2788889277 crossrefType "journal-article" @default.
• W2788889277 hasAuthorship W2788889277A5005621340 @default.
• W2788889277 hasAuthorship W2788889277A5006308233 @default.
• W2788889277 hasAuthorship W2788889277A5011411233 @default.
• W2788889277 hasAuthorship W2788889277A5030167766 @default.
• W2788889277 hasAuthorship W2788889277A5045621454 @default.
• W2788889277 hasAuthorship W2788889277A5046031005 @default.
• W2788889277 hasAuthorship W2788889277A5049940232 @default.
• W2788889277 hasAuthorship W2788889277A5054372225 @default.
• W2788889277 hasAuthorship W2788889277A5068335479 @default.
• W2788889277 hasAuthorship W2788889277A5076087889 @default.
• W2788889277 hasBestOaLocation W27888892772 @default.
• W2788889277 hasConcept C121608353 @default.
• W2788889277 hasConcept C126322002 @default.
• W2788889277 hasConcept C143998085 @default.
• W2788889277 hasConcept C168563851 @default.
• W2788889277 hasConcept C2777088508 @default.
• W2788889277 hasConcept C29456083 @default.
• W2788889277 hasConcept C535046627 @default.
• W2788889277 hasConcept C71924100 @default.
• W2788889277 hasConceptScore W2788889277C121608353 @default.
• W2788889277 hasConceptScore W2788889277C126322002 @default.
• W2788889277 hasConceptScore W2788889277C143998085 @default.

• next